Potential vaccine approaches
| Type of vaccines . |
|---|
| Idiotype (Id) vaccines + adjuvants |
| Dendritic cells + Id |
| Dendritic cell tumor fusion vaccine |
| Dendritic cells + cancer testis antigen |
| Dendritic cells electroporated with mRNA of target antigens |
| Peptide vaccine + adjuvant |
| Allogeneic myeloma cell lines with GM–CSF bystander line |
| Type of vaccines . |
|---|
| Idiotype (Id) vaccines + adjuvants |
| Dendritic cells + Id |
| Dendritic cell tumor fusion vaccine |
| Dendritic cells + cancer testis antigen |
| Dendritic cells electroporated with mRNA of target antigens |
| Peptide vaccine + adjuvant |
| Allogeneic myeloma cell lines with GM–CSF bystander line |
| Settings where vaccines are tested in clinical trials . |
|---|
| Sustained near complete remission (nCR) for 4 months |
| Post auto-SCT |
| Post allo-SCT |
| Undergoing auto-SCT |
| Newly diagnosed on maintenance lenalidomide |
| Symptomatic MM |
| Off treatment with stable disease |
| Smoldering myeloma |
| Settings where vaccines are tested in clinical trials . |
|---|
| Sustained near complete remission (nCR) for 4 months |
| Post auto-SCT |
| Post allo-SCT |
| Undergoing auto-SCT |
| Newly diagnosed on maintenance lenalidomide |
| Symptomatic MM |
| Off treatment with stable disease |
| Smoldering myeloma |
| Vaccine antigens tested in clinical trials . |
|---|
| hTERT peptides: I540, R572Y, D988Y |
| Survivin peptide: Sur1M2, SVN53-67/M57, |
| KLH-Id |
| WT1 peptides: A1, 427, 331, 122A1 |
| MAGE-A3: GL-0817, 168-176 |
| NY-ESO-1: 1156-C165V, |
| XBP1: US(184-192), SP(367-375) |
| CD138: (260-268) |
| CS1: (239-247) |
| MUC1: BP25 |
| Vaccine antigens tested in clinical trials . |
|---|
| hTERT peptides: I540, R572Y, D988Y |
| Survivin peptide: Sur1M2, SVN53-67/M57, |
| KLH-Id |
| WT1 peptides: A1, 427, 331, 122A1 |
| MAGE-A3: GL-0817, 168-176 |
| NY-ESO-1: 1156-C165V, |
| XBP1: US(184-192), SP(367-375) |
| CD138: (260-268) |
| CS1: (239-247) |
| MUC1: BP25 |